Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

Conclusion:
Observed reduction in relapse rates reflected those reported in clinical trials, but we were unable to corroborate previous observations of disability reversal. 40% of patients required additional treatment cycles. Autoimmune adverse events were common, occurring at a higher rate than previously reported, but were largely predictable, and could be managed effectively within a rigorous monitoring regime.

Source: Multiple Sclerosis - July 25, 2016 Category: Neurology Authors: Willis, M., Harding, K., Pickersgill, T., Wardle, M., Pearson, O., Scolding, N., Smee, J., Robertson, N. Tags: July 2016 22 (8) Original Research Papers Source Type: research